We are live on ! Find out more
GANX icon

Gain Therapeutics
GANX

23 hedge funds and large institutions have $3.95M invested in Gain Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

44% more funds holding

Funds holding: 16 → 23 (+7)

1.17% more ownership

Funds ownership: 9.05% → 10.21% (+1.2%)

2% more capital invested

Capital invested by funds: $3.87M → $3.95M (+$85.9K)

Holders
23
Holders Change
+7
Holders Change %
+43.75%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
7
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$234K
2
WAAG
Wealth Alliance Advisory Group
Kansas
+$93.9K
3
RJA
Raymond James & Associates
Florida
+$90.2K
4
Northern Trust
Northern Trust
Illinois
+$47.1K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$44.9K

Top Sellers

Rank Fund Capital Flow
1
TI
Telemetry Investments
New York
-$37.6K
2
UBS Group
UBS Group
Switzerland
-$8.6K
3
BlackRock
BlackRock
New York
-$2.4K
4
Osaic Holdings
Osaic Holdings
Arizona
-$376
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$1.78M – – –
TI
2
Telemetry Investments
New York
$489K -$37.6K -10,000 -6%
CM
3
CM Management
Florida
$408K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$286K +$234K +62,149 +241%
PCM
5
Prelude Capital Management
New York
$189K – – –
BCM
6
Bridgeway Capital Management
Texas
$130K – – –
Royal Bank of Canada
7
Royal Bank of Canada
Ontario, Canada
$127K +$323 +86 +0.2%
Renaissance Technologies
8
Renaissance Technologies
New York
$109K +$1.13K +300 +0.9%
WAAG
9
Wealth Alliance Advisory Group
Kansas
$82K +$93.9K +25,000 New
RJA
10
Raymond James & Associates
Florida
$78K +$90.2K +24,000 New
BlackRock
11
BlackRock
New York
$75K -$2.4K -640 -3%
Northern Trust
12
Northern Trust
Illinois
$41K +$47.1K +12,546 New
CC
13
Cannell Capital
Wyoming
$40K +$36.1K +9,620 +350%
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$39K +$44.9K +11,942 New
Osaic Holdings
15
Osaic Holdings
Arizona
$33K -$376 -100 -1%
TRCT
16
Tower Research Capital (TRC)
New York
$17K +$17.1K +4,545 +635%
UBS Group
17
UBS Group
Switzerland
$13K -$8.6K -2,289 -36%
Wells Fargo
18
Wells Fargo
California
$9K +$135 +36 +1%
Morgan Stanley
19
Morgan Stanley
New York
$4K +$947 +252 +32%
HI
20
Hoey Investments
Pennsylvania
$2K – – –
JP Morgan Chase
21
JP Morgan Chase
New York
$2K +$2.23K +594 New
BNP Paribas Financial Markets
22
BNP Paribas Financial Markets
France
$923 +$1.06K +283 New
Simplex Trading
23
Simplex Trading
Illinois
– +$376 +100 New

GANX Hedge Fund Activity: Q3 2022 in Review

23 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q3 2022, worth a combined $3.95M — up 2.2% from $3.87M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new GANX positions and 0 closed out — a net gain of 7 holders — while 7 added to existing stakes and 4 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $234K. The largest seller was Telemetry Investments, cutting an estimated $37.6K.

  • 23 institutional investors held Gain Therapeutics (GANX) as of Q3 2022, up from 16 in Q2 2022.
  • Funds reported $3.95M of Gain Therapeutics stock for Q3 2022, up 2.2% quarter-over-quarter.
  • 7 funds opened new Gain Therapeutics positions in Q3 2022 and 0 closed out, a net change of +7 holders.
  • The largest Gain Therapeutics buyer in Q3 2022 was Geode Capital Management, an estimated $234K added.
  • The largest Gain Therapeutics seller in Q3 2022 was Telemetry Investments, an estimated $37.6K sold.

Based on aggregated 13F filings for Q3 2022.